Firvanq Shortage: What Providers and Prescribers Need to Know in 2026

For clinicians managing Clostridioides difficile (CDI) and staphylococcal enterocolitis, Firvanq (vancomycin hydrochloride for oral solution) is a critical tool — particularly for patients who cannot swallow capsules. But inconsistent pharmacy stocking of this specialty liquid antibiotic is creating real challenges at the point of discharge and in outpatient settings. This guide gives you the current supply landscape, clinical decision trees, and practical strategies to protect patient outcomes when Firvanq isn't readily available.

Current Supply Landscape: What Clinicians Need to Know

Firvanq is not on the FDA's official shortage list as of 2026. However, availability is inconsistent across retail pharmacy networks. The broader vancomycin supply chain remains stressed, with the ASHP listing IV vancomycin in active shortage since 2023 due to constraints at multiple manufacturers including Fresenius Kabi, Pfizer/Hospira, Hikma, and Xellia. While oral formulations are less severely affected, the upstream supply pressure creates intermittent stocking gaps for Firvanq.

Key finding for discharge planning: Specialty pharmacies and hospital outpatient pharmacies are far more reliable sources for Firvanq than standard retail chains. Many retail pharmacies don't routinely stock Firvanq and may take 1-3 business days to obtain it — a clinically unacceptable delay for active CDI.

Updated Treatment Guidelines: What's Changed Since 2021

The 2021 IDSA/SHEA focused update fundamentally changed the preferred treatment hierarchy for CDI:

• Fidaxomicin (Dificid) is now the preferred first-line agent for non-fulminant CDI in adults and children ≥6 months, based on a demonstrated ~40% reduction in recurrence rates compared to vancomycin. Dosing: 200 mg twice daily for 10 days.
• Oral vancomycin remains an acceptable alternative for initial and recurrent CDI. Standard dose: 125 mg four times daily for 10 days. For recurrent CDI, a tapered and pulsed regimen may improve outcomes.
• Fulminant CDI (hypotension, shock, ileus, megacolon): vancomycin 500 mg q6h PO/NG tube + IV metronidazole 500 mg q8h. Consider rectal vancomycin (500 mg in 100 mL NS as retention enema q6h) if ileus is present.
• Metronidazole is no longer recommended as monotherapy for CDI. Use only when vancomycin and fidaxomicin are both genuinely unavailable for mild cases.

When Firvanq Is Specifically Required: Who Needs the Liquid Form?

Firvanq's clinical niche is patients who genuinely cannot tolerate capsules. Identify these patients early during hospitalization so alternative sourcing can begin before discharge:

• Elderly patients with dysphagia or severe odynophagia
• Pediatric patients (Firvanq is approved for children <18 years)
• Patients with feeding tubes (NG, G-tube, J-tube) where liquid formulations are required
• Patients with neurological conditions affecting swallowing (post-stroke, ALS, Parkinson's)

Clinical Alternatives When Firvanq Is Unavailable

When Firvanq cannot be sourced in time, consider the following alternatives in clinical order of preference:

1. Compounded oral vancomycin solution. Many compounding pharmacies can prepare vancomycin oral solution from IV powder, often within hours. Write a compounding prescription specifying vancomycin hydrochloride oral solution with the appropriate concentration (e.g., 25 mg/mL or 50 mg/mL). Clinically equivalent to Firvanq.
2. Fidaxomicin oral granules for suspension (Dificid). Approved for children ≥6 months, fidaxomicin is available as an oral suspension formulation (granules for suspension). This may be a viable alternative for pediatric patients who need a liquid and for whom vancomycin solution cannot be sourced.
3. Generic vancomycin capsule contents in liquid. For patients who require liquid but for whom compounding is not an option, vancomycin capsule contents can be opened and dissolved in a small amount of water or juice. Instruct patients to take the full prepared dose immediately and not to pre-mix doses.

38,375+ patients found their medications in stock

38K+

Find Firvanq In Stock Today →

Discharge Planning Recommendations

To minimize post-discharge delays and interruptions to therapy:

• Confirm Firvanq availability at the patient's preferred pharmacy before discharge, ideally 24 hours in advance
• Send prescriptions electronically to hospital outpatient or specialty pharmacies whenever possible
• Provide patients with a 2-3 day supply from the hospital pharmacy to bridge any gap while outpatient sourcing is confirmed
• Document the liquid requirement clearly in the prescription to prevent pharmacist substitution of capsules without notification
• Direct patients to medfinder for providers — a service that helps patients call pharmacies to verify Firvanq stock near their home address before discharge

Patient Counseling Points

Ensure patients understand the following before leaving the hospital or clinic:

• Firvanq must be refrigerated after reconstitution and discarded after 14 days
• Shake the bottle well before each dose and use an oral measuring device — household spoons are inaccurate
• Complete the full course even if symptoms improve — premature discontinuation risks relapse
• Monitor for signs of nephrotoxicity, especially in patients with pre-existing renal impairment or concurrent aminoglycoside use

For practical guidance on helping patients locate Firvanq at discharge, see our companion post: How to help your patients find Firvanq in stock: a provider's guide.